抗线粒体抗体M2亚型检测的经济价值研究

The assessment of economic value of anti-mitochondrial antibody-M2 clinical detection

目的 :通过在体检人群中筛查抗线粒体抗体M2亚型(anti-mitochondrial antibody-M2,AMA-M2)以期提高原发性胆汁性肝硬化(PBC)的检出率,并评估该指标普查的经济价值。方法 :运用卫生经济学中的成本效益法,测算区域性及全国性通过AMA-M2筛查PBC患者的经济效益。结果 :无论在直接的医疗成本还是生命年价值上,通过AMA-M2早期筛查PBC将对患者及社会带来巨大的经济效益。结论 :将AMA-M2检测作为我国常规健康体检筛查指标是提高PBC检出率并降低治疗成本的重要途径。

Objective： To increase the detection rate of primary biliary cirrhosis（ PBC ）through testing anti-mitochondrial antibody-M2 （ AMA-M2 ） and to evaluate the economic value of the indication. Methods： Costeffectiveness method was used to measure the economic value of screening PBC patients with AMA-M2 regionally and nationally. Results ： Early screening of AMA-M2 in patients with PBC could bring extraordinary economic benefits to patients and the society from both direct medical costs and life value perspective. Conclusion： It is suggested that AMA-M2 should be enrolled as one of the routine indexes of health examination in China, which is an important way to increase PBC detection rate and decrease treatment cost.